Standard Dosing for Metastatic Lung Adenocarcinoma
For metastatic lung adenocarcinoma, the standard first-line regimen is pemetrexed 500 mg/m² plus carboplatin AUC 5-6 every 21 days for 4-6 cycles, followed by pemetrexed maintenance. This applies to patients without actionable mutations (EGFR, ALK, ROS1) and should be combined with pembrolizumab in most cases unless contraindicated 1, 2, 3, 2.
Specific Dosing Recommendations
Pemetrexed Dosing
- Standard dose: 500 mg/m² IV every 21 days 2
- Requires mandatory supplementation with:
- Folic acid 400-1000 mcg daily starting 7 days before first dose
- Vitamin B12 1000 mcg IM every 9 weeks starting 7 days before first dose
- Dexamethasone 4 mg PO twice daily for 3 days (day before, day of, and day after pemetrexed)
Carboplatin Dosing
- Preferred: AUC 5 using Calvert formula 4, 5
- Alternative: AUC 6 (higher toxicity without survival benefit) 5
- Calvert Formula: Total Dose (mg) = Target AUC × (GFR + 25) 4
The evidence strongly favors AUC 5 over AUC 6. A meta-analysis of 486 patients demonstrated that carboplatin AUC 5 had significantly lower rates of thrombocytopenia (all grades and grade 3/4), anemia, neutropenia, fatigue, and vomiting compared to AUC 6, with equivalent survival outcomes 5. Multiple Asian studies confirm AUC 4-5 provides adequate efficacy with better tolerability 6, 7, 8.
Treatment Duration
Dose Adjustments for Liver Function Test Abnormalities
Critical Distinction: Pemetrexed vs Carboplatin
Pemetrexed is NOT hepatically eliminated and does NOT require dose reduction for isolated LFT elevations. The drug is primarily renally excreted (70-90% unchanged in urine), making renal function—not hepatic function—the critical determinant of dosing 9.
Carboplatin is also primarily renally eliminated (65% in 12 hours, 71% in 24 hours) and does NOT require hepatic dose adjustment 4.
When to Hold or Reduce Doses
For Pemetrexed:
Hold treatment if:
- Total bilirubin >1.5× ULN
- AST/ALT >3× ULN (or >5× ULN if liver metastases present)
- Alkaline phosphatase >3× ULN
Resume at 75% dose when:
- Total bilirubin ≤1.5× ULN
- Transaminases return to ≤3× ULN
For Carboplatin:
No specific hepatic dose adjustments are required 4. The FDA label does not mandate dose reductions for LFT abnormalities alone.
However, hold both drugs if:
- Grade 3-4 hepatotoxicity develops during treatment
- Clinical hepatic decompensation occurs
- Bilirubin >3× ULN (suggests severe hepatic dysfunction)
Renal Function Takes Priority
This is the critical adjustment you must make: Both drugs require dose modification for renal impairment, which is far more clinically relevant than hepatic dysfunction.
Carboplatin Renal Dosing 4:
| Creatinine Clearance | Recommended Dose |
|---|---|
| 41-59 mL/min | 250 mg/m² |
| 16-40 mL/min | 200 mg/m² |
| <15 mL/min | Insufficient data; avoid |
Pemetrexed Renal Dosing:
- CrCl ≥45 mL/min: Full dose (500 mg/m²)
- CrCl <45 mL/min: Contraindicated 8
The pharmacokinetic study by Okamoto et al. demonstrated a significant inverse correlation between pemetrexed AUC and creatinine clearance, with increased hematologic toxicity in patients with renal dysfunction 8.
Hematologic Dose Modifications (More Relevant Than LFTs)
Before each cycle, check CBC. Delay treatment until recovery:
| Toxicity | Nadir Values | Dose Adjustment |
|---|---|---|
| Platelets <100,000 AND/OR Neutrophils <2,000 | Hold until recovery | Resume at 75% dose |
| Platelets 50,000-100,000 OR Neutrophils 500-2,000 | Hold until recovery | Resume at 100% dose |
| Platelets <50,000 OR Neutrophils <500 | Hold until recovery | Resume at 75% dose |
Common Pitfalls to Avoid
Do not reflexively reduce doses for mild LFT elevations (1.5-3× ULN) if liver metastases are present—this is expected and does not require adjustment unless accompanied by clinical hepatic dysfunction.
Do not confuse hepatic metabolism with hepatic toxicity. Neither drug requires dose reduction based on baseline hepatic impairment unless it's severe (Child-Pugh C).
Always calculate carboplatin dose using measured or estimated GFR, not BSA alone. The Calvert formula accounts for renal function, which is the primary determinant of carboplatin clearance 4.
Monitor for cumulative toxicity. If LFTs progressively worsen during treatment (not just baseline elevation), hold therapy and investigate for drug-induced liver injury, disease progression, or other causes.
Elderly patients (≥70 years) tolerate carboplatin AUC 5 better than AUC 6 without compromising efficacy 7, 8, 10. Consider starting at AUC 5 in this population.